Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.3
Journals
Pharmaceuticals
Special Issues
Advances in the Treatment of Leukemia and Lymphomas
share announcement

Advances in the Treatment of Leukemia and Lymphomas

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 25 September 2025 | Viewed by 278

Special Issue Editors

Dr. Adriano de Paula Sabino

E-Mail Website
Guest Editor
Laboratório Institucional de Pesquisa em Biomarcadores, Laboratório de Hematologia Clínica, Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, Brazil
Interests: cancer; leukemia; chemotherapy; biomarkers; genomics; proteomics; metabolomics; nanobiomaterials; regenerative medicine; cell therapy; bioinformatics applied to these fields
Prof. Dr. Karina Braga Gomes

E-Mail Website
Guest Editor
1. Faculty of Medicine, Federal University of Minas Gerais, Professor Alfredo Balena Avenue, 190, Santa Efigênia, Belo Horizonte 30130-100, MG, Brazil
2. Department of Clinical and Toxicological Analyzes, Faculty of Pharmacy, Federal University of Minas Gerais, Presidente Antônio Carlos Avenue, 6627, Pampulha, Belo Horizonte 31270-901, MG, Brazil
Interests: biomarkers of insulin resistance; diabetes; cardiovascular disease and dementia; translational neuroscience
Prof. Dr. Maria Das Graças Carvalho

E-Mail Website
Guest Editor
Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil
Interests: laboratory hematology; hemostasis (thrombin generation tests under different experimental conditions); hemostatic disorders in general (particularly states associated with hypercoagulability)

Special Issue Information

Dear Colleagues,

Leukemia and lymphomas are malignant hematological disorders that have historically posed significant challenges to patients and clinicians. Over the past decades, ongoing research and technological advances have substantially improved diagnostic capabilities, risk stratification, and survival.

Recent developments, including novel agents such as gemtuzumab ozogamicin, blinatumumab, zanabrutinib, and venetoclax, underscore the expanding options for patients with different disease subtypes. Advances in immunotherapy platforms and precision medicine approaches are driving improvements in patient outcomes and quality of life.

This Special Issue aims to collate the latest innovations and clinical insights propelling the field toward more effective treatments and personalized care. We seek to highlight the interplay between novel diagnostic tools, targeted therapeutics, and emerging cellular therapies that will define the future of hematologic oncology. By fostering multidisciplinary collaboration, we hope to accelerate the translation of groundbreaking discoveries into clinical practice.

We invite original research articles, reviews, and clinical studies that explore innovative treatment strategies, translational efforts, and the broader implications of these emerging therapies. Established experts and new hematologic oncology investigators are encouraged to submit their findings.

Dr. Adriano de Paula Sabino
Prof. Dr. Karina Braga Gomes
Prof. Dr. Maria Das Graças Carvalho
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • leukemias
  • lymphomas
  • chemotherapy
  • target therapy
  • immunotherapy
  • kinase inhibitors
  • hematologic oncology
  • therapy
  • treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 2213 KiB  
Article
XMU-MP-1, Inhibitor of STE20-like MST1/2 Kinases of the Hippo Signaling Pathway, Suppresses the Cell Cycle, Activates Apoptosis and Autophagy, and Induces Death of Hematopoietic Tumor Cells
by Alexander G. Stepchenko, Sofia G. Georgieva and Elizaveta V. Pankratova
Pharmaceuticals 2025, 18(6), 874; https://doi.org/10.3390/ph18060874 - 12 Jun 2025
Viewed by 61
Abstract
Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach [...] Read more.
Background/Objectives: Currently, there is limited knowledge on the molecular mechanisms of the “non-canonical” Hippo signaling pathway in hematopoietic tumor cells. We have shown that targeting the MST1/2 kinases, which are the key molecules in this signaling pathway, may be an effective approach to the treatment of hematologic tumors. Methods: The methods used in this study include cell growth assays, caspase assays, Western blot hybridizations, flow cytometry, and whole-transcriptome analyses. These methods allowed us to better understand the molecular pathways at play. Results: Our results showed that XMU-MP-1, an inhibitor of MST1/2 kinase, specifically reduces the viability of hematopoietic cancer cells but not breast cancer cells. It effectively inhibits the growth of the tumor B- and T-cell lines by blocking cell cycle progression, mainly during the G2/M phase, inducing apoptosis and autophagy. XMU-MP-1 treatment led to increased caspase 3/7 activity and increased levels of the cleaved PARP protein. Levels of the LC3-II protein were also shown to be increased, while the level of p62 decreased. These changes are associated with apoptosis and autophagy, respectively. RNA-seq analysis has demonstrated that XMU-MP-1 suppressed the expression of cell cycle regulators, such as E2F, and cell division cycle genes CDC6,7,20,25,45; cyclins A2,B1,B2, and cyclin-dependent kinases. At the same time, it increased the expression of genes involved in apoptosis, autophagy, and necroptosis. Conclusions: Combinations of growth assays, caspase assays, Western blotting, and RNA-seq have shown that the dramatic reduction in the number of hematopoietic tumor cells after treatment with XMU-MP-1 is due to both cytostatic and cytotoxic effects. The use of MST1/2 kinase inhibitors could be highly promising for complex therapy of hematological tumors. Full article
(This article belongs to the Special Issue Advances in the Treatment of Leukemia and Lymphomas)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop